Comprehensive profiling of biomarkers linked to inflammatory, autoimmune, and infectious diseases is critical for advancing diagnostic and therapeutic development. Progress in this area has been constrained by the lack of highly sensitive multiplex platforms that can detect across the large dynamic range of protein concentrations. To address this gap, we developed NULISAseq Immune 340 Panel, enabling simultaneous quantification of over 340 proteins involved in inflammation and immunology. The panel provides comprehensive coverage of critical pathways, including apoptosis, immune checkpoints, complement activation, and key disease-associated markers relevant to systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), inflammatory bowel disease (IBD), sepsis, and cancer.

This high multiplex assay was optimized for plasma and serum and underwent extensive analytical characterization to assess precision, reproducibility, detectability, specificity, and dilution linearity. Results demonstrated strong analytical robustness, with median intra- and inter-plate CV below 10%. Over 90% of targets exhibited excellent dilutional linearity (RSQ >0.9) and >90% detectability in plasma and serum samples with high signal-to-noise ratios, while cross-reactivity remained under 1%, confirming high specificity. The novel panel also showed a very high correlation to our existing Inflammation 250 panel for the overlapping targets, representing high analytical robustness and accuracy. These findings underscore the potential of this platform to uncover novel disease mechanisms and enable patient stratification based on molecular profiles.

In summary, the NULISAseq Immune 340 Panel represents significant advancement in immune biomarker analysis, combining breadth, sensitivity, and reproducibility in a single assay. By enabling deep characterization of immune pathways across diverse conditions, it opens new opportunities for early disease detection and longitudinal monitoring in biofluids.